Aclaris Therapeutics (ACRS)

• Market cap: $123M
• 1 day: 0.88%
• 5 days: 2.70%
• 1 month: -27.85%
• 3 months: -55.64%
• 6 months: -2.56%
• Year to date: -54.03%
• 1 year: -7.32%
• 5 years: -5.00%
• 10 years: -89.68%
• Sector: Healthcare
• Industry: Diagnostics & Research

About: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Employees: 64

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

271% more capital invested

Capital invested by funds: $58.5M [Q3] → $217M (+$159M) [Q4]

128% more call options, than puts

Call options by funds: $850K | Put options by funds: $372K

127% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 15

100% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]

51.16% more ownership

Funds ownership: 71.33% [Q3] → 122.49% (+51.16%) [Q4]

21% more funds holding

Funds holding: 80 [Q3] → 97 (+17) [Q4]

4% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 24

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $15 1,216% upside
• Avg. target: $15 1,216% upside
• High target: $15 1,216% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Scotiabank Louise Chen 19% 1-year accuracy 23 / 120 met price target

1,216% upside $15

Sector Outperform Initiated

7 Mar 2025